The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients

Transplant International

Volumn 23, Issue 8, 2010, Pages 786-795

  Scarsi, Mirko ^a   Bossini, Nicola ^a   Malacarne, Fabio ^a   Valerio, Francesca ^a   Sandrini, Silvio ^a   Airò, Paolo ^a  

^a Rheumatology and Clinical Immunology Service   (Italy)

Author keywords

alemtuzumab; kidney transplantation; recent thymic emigrants; T cells

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CD31 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER ANTIBODY; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTOPENIA; MALE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL MOTION; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKAPHERESIS; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; THYMUS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOCYTE REDUCTION PROCEDURES; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; THYMUS GLAND;

EID: 77954505350     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01052.x     Document Type: Article

References (39)

1. Calne R, Moffatt SD, Friend PJ, et al. Campath-1H allows low dose cyclosporine therapy in 31 cadaveric renal allograft recipients. Transplantation 1999 68 : 1613.
2. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 76 : 120.
3. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005 5 : 1347.
4. Knechtle SJ, Pirsch JD, Fechner JH Jr., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003 3 : 722.
5. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004 78 : 426. (Pubitemid 39095410)
6. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005 80 : 765. (Pubitemid 41443758)
7. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing and newer immune-monitoring. Transplantation 2005 80 : 457. (Pubitemid 41209412)
8. Brett S, Baxter G, Cooper H, et al. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996 88 : 13. (Pubitemid 126423686)
9. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006 81 : 81. (Pubitemid 43122153)
10. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465. (Pubitemid 40313337)
11. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after Campath-1H induction with reduced maintenance immunosuppression. Transplantation 2006 82 : 1342. (Pubitemid 44834311)
12. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999 401 : 708. (Pubitemid 129515761)
13. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4+ T Cells. J Exp Med 2001 194 : 1711. (Pubitemid 34028651)
14. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003 101 : 4260. (Pubitemid 36857786)
15. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev 2006 127 : 274. (Pubitemid 43214500)
16. Weninger W, Crowley MA, Manjunath N, von Adrian UH. Migratory properties of naïve, effector and memory CD8+ cells. J Exp Med 2001 194 : 953. (Pubitemid 32953264)
17. Kimmig S, Przybylski GK, Schmidt CA, et al. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med 2002 195 : 789. (Pubitemid 34259723)
18. Junge S, Kloeckener-Gruissem B, Zufferey R. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol 2007 37 : 3270. (Pubitemid 350131305)
19. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 351 : 1701. (Pubitemid 28254534)
20. Ciancio GC, Burke GW. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008 8 : 15.
21. Ortiz J, Palma-Vargas J, Wright F, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008 85 : 1550.
22. Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4+ and CD8+ T cells in peripheral blood. Transpl Int 2006 19 : 927. (Pubitemid 44511118)
23. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev 2005 205 : 257. (Pubitemid 40780191)
24. Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 2004 34 : 3525. (Pubitemid 40012170)
25. Yeo FE, Yuan CM, Swanson SJ, et al. The prevalence of BK polyomavirus infection in outpatient kidney transplant recipients followed in a single center. Clin Transplant 2008 22 : 532.
26. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007 84 : 1436. (Pubitemid 350294718)
27. Sewgobind VDKD, Kho MML, Van der Laan LJW, et al. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 2009 24 : 1635.
28. Hazenberg MD, Borghans JAM, de Boer RJ, Miedema F. Thymic output: a bad TREC record. Nat Immunol 2003 4 : 97. (Pubitemid 36193005)
29. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983 62 : 873. (Pubitemid 13008678)
30. Patel DD, Whichard LP, Radcliff G, Denning SM, Haynes BF. Characterization of human thymic epithelial cell surface antigens: phenotypic similarity of thymic epithelial cells to epidermal keratinocytes. J Clin Immunol 1995 15 : 80.
31. Rezvany MR, Tehrani MJ, Karlsson C, et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Brit J Haematol 2006 135 : 475. (Pubitemid 44583411)
32. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009 119 : 2052.
33. Thachil J, Jadhav V, Gautam M, et al. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Brit J Haematol 2007 138 : 555. (Pubitemid 47063037)
34. Zenz T, Ritgen M, Dreger P, et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukaemia. Blood 2006 108 : 2127. (Pubitemid 44395031)
35. Watanabe T, Masuyama JI, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006 120 : 247. (Pubitemid 44175899)
36. Morales J, Bono MR, Fierro A, et al. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Transplant Proc 2008 40 : 3223.
37. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008 8 : 1529. (Pubitemid 351989487)
38. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008 8 : 793.
39. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009 9 : 1087.